Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. - Wikidata - wikimedia - TriplyDB

Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

http://www.wikidata.org/entity/Q35914312

about

AID and APOBECs span the gap between innate and adaptive immunity Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1 Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors Human LINE-1 restriction by APOBEC3C is deaminase independent and mediated by an ORF1p interaction that affects LINE reverse transcriptase activity HIV-1 Vif, APOBEC, and intrinsic immunity Human cytidine deaminase APOBEC3H restricts HIV-1 replication Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1 A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity Cytidine deamination induced HIV-1 drug resistance 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G HIV Genome-Wide Protein Associations: a Review of 30 Years of Research Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all Suppression of APOBEC3-mediated restriction of HIV-1 by Vif APOBEC3 Interference during Replication of Viral Genomes Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components A symmetric region of the HIV-1 integrase dimerization interface is essential for viral replication APOBEC3G: an intracellular centurion Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.SIV replication in human cells The restriction of zoonotic PERV transmission by human APOBEC3G.APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.APOBEC3G inhibits elongation of HIV-1 reverse transcripts.Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins Inducible APOBEC3G-Vif double stable cell line as a high-throughput screening platform to identify antiviral compounds.R88-APOBEC3Gm Inhibits the Replication of Both Drug-resistant Strains of HIV-1 and Viruses Produced From Latently Infected Cells Changes in the accessibility of the HIV-1 Integrase C-terminus in the presence of cellular proteins.Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination.

P2860

Q21131084-EF5586EB-97B6-4656-B377-CE34CCBF0140 Q21131577-01F496BB-1E7B-44B8-9A5E-F1D16708D9BA Q24317568-21466405-6EAE-46DF-868A-47C8080E94A4 Q24612992-0A337704-9A21-4163-893F-8B572285CBEC Q24618320-3B719477-947B-473E-A822-67CAE5E1BDB6 Q24619114-DABD2099-8C4D-4F44-9DD2-CBBD77E36DDD Q24625056-AB03C657-E56F-4E5B-AC49-81DA0ED7BEF4 Q24647833-7A4DD275-DA54-4E31-872A-3BBE54FD46FC Q24653682-3FCE386D-041C-44A2-9A3E-9F0E9A43674D Q24655541-02BD497E-8E35-4F15-96C5-9DFE657C74A0 Q24656551-ED7241BD-A26F-47EC-A117-5BC912B5C896 Q24657298-BDC35889-90D2-4B1B-9E23-E579B9D3B28F Q24681427-0EEE76B4-E3AB-42E7-82E0-E9E2E4392923 Q26746070-11D7A9E3-469F-4CFE-9D71-95E2160CB3E0 Q26823568-4FC67C03-11CD-42FC-B15E-13CAD7D2232D Q27025150-10A94083-6FF7-44DD-87F4-A00E102D0AE5 Q28081195-82CF5490-33E1-4939-820E-13E3F9D8B6B1 Q28480578-D1134D56-D846-488C-99B4-07BC71FB73F0 Q28482052-D8A94EBB-F257-4836-AE0F-6B66C721BFB5 Q28483813-1D03088C-2CA8-49B4-B0EC-8079BEA9CE8C Q28754989-884ABED3-F20C-4952-94BF-7F52D043DC4D Q30381745-A794B8C5-BE98-4B9E-8958-BE5A81E29AF6 Q30417737-E98E4B43-24D6-42A8-9389-CD6F8DE735E6 Q33298609-5734567B-8CCF-432F-BFC0-DD9DBFF6973D Q33349452-245879BF-AC3D-4B92-9F8A-06EF6A5D246E Q33389841-8B219B97-CD3F-4150-AF0E-60B277A28D40 Q33393637-0C93268E-E092-4830-A988-9DBCFDE36A9B Q33511412-351ABA1F-7A6D-45F5-97EF-B0BD213008C1 Q33637221-EB3FAE37-578B-45DF-BDCE-F76F026B0DB8 Q33810773-2E4D5489-779F-4AFA-A073-5227864BFC93 Q33815187-16809D69-9BBC-455D-BC79-E0A8674503A0 Q33826857-2E6E2724-7541-4863-B4F2-D9153DEAE319 Q33826968-03FEB930-31E7-48B1-ABC5-6A3CAE450FDA Q33877299-72FB0DF8-675A-4907-AFE5-102ED04903BC Q34083646-F9C22CF1-B85F-43F6-8AD3-395CEAC2B853 Q34107265-6BB4B745-889D-403E-AC47-8A2DE8085D16 Q34120265-6FCABA85-BEF0-453E-8E14-4788301B3088 Q34120768-E1561786-20B8-473E-A538-97A9D71D70F1 Q34121572-C390B685-68F5-4614-BA43-A71A0896719B Q34166447-B40AAC6E-81F1-4044-A14B-96E23F98BAB7

P2860

Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

http://www.wikidata.org/entity/Q35914312

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Cytidine deaminases APOBEC3G a ...... nhibit proviral DNA formation.

@ast

Cytidine deaminases APOBEC3G a ...... nhibit proviral DNA formation.

@en

type

label

Cytidine deaminases APOBEC3G a ...... nhibit proviral DNA formation.

@ast

Cytidine deaminases APOBEC3G a ...... nhibit proviral DNA formation.

@en

prefLabel

Cytidine deaminases APOBEC3G a ...... nhibit proviral DNA formation.

@ast

Cytidine deaminases APOBEC3G a ...... nhibit proviral DNA formation.

@en

P1433

Q35914312-F050213D-48C5-4857-A966-16CD4CBE5F84

P1476

Q35914312-4E4E1BCF-B64B-4E38-9041-417CD3B7D5D0

P2093

Q35914312-157BF506-E44F-4C58-B43D-306764026C08

Q35914312-341E418D-2AB4-4CC6-A8DB-120072D1C080

Q35914312-62C0B527-75D6-4B89-B6DC-03BCCD72493D

Q35914312-6BF282CA-9037-4BC3-81D4-0A2E15F116B8

Q35914312-962E9857-BF0B-4C5E-9CB3-A65F60BE4113

Q35914312-D0247601-B3B4-492D-A388-B382A7B39C8F

Q35914312-FD4B54D1-9304-4366-BABB-709ACB84CC03

P2860

Q35914312-0399D63C-8407-47AA-BF71-19E43631DE04

Q35914312-03B42555-AE08-4E9B-A494-6ED0F66F1DBF

Q35914312-0B1E4606-3A77-481C-BAA2-46C2710B617E

Q35914312-11248575-8F10-47D8-8C96-E796C92DA6DA

Q35914312-11AC1C15-F473-4AE6-90D6-3D9B85B8E3D6

Q35914312-1A0BAABA-7C37-4C93-891C-9D03636D0C50

Q35914312-209A3DCA-25CA-4FC7-9FF1-4E02FB498832

Q35914312-23605AF1-CC57-44DD-A61E-B5389B403B56

Q35914312-24598722-7F92-466F-942B-EC2DD4A5B668

Q35914312-2A91D5A0-1619-4531-8C37-B117794D2188

P304

Q35914312-C9172599-4573-4B6A-9E39-95471E141402

P31

Q35914312-F8B260F7-C676-48E1-A9F4-B1303854362F

P356

Q35914312-238F45A0-776D-4D6A-89FE-E787089F781C

P407

Q35914312-848CD880-D51F-4842-BE69-96C68C175E0E

P433

Q35914312-82140995-7AC4-4A4B-A262-BF0DFB30078D

P478

Q35914312-52E22117-AD8F-4C42-8D4E-9C8CA3069DB1

P577

Q35914312-9368C842-EE4D-49DC-89D4-44B3F5C9D134

P5875

Q35914312-D4B6F06A-DEC4-4344-8FF3-2C9E837B140B

P698

Q35914312-243D8D96-96C1-4172-B62E-7C9B80C26D87

P932

Q35914312-83FDC9F6-324A-4BB1-B36D-AC17094B0808

P356

P1433

Journal of Virology

P1476

Cytidine deaminases APOBEC3G a ...... nhibit proviral DNA formation.

@en

P2093

Bindong Liu

http://www.w3.org/2001/XMLSchema#string

Chunjuan Tian

http://www.w3.org/2001/XMLSchema#string

John Kappes

http://www.w3.org/2001/XMLSchema#string

Kun Luo

http://www.w3.org/2001/XMLSchema#string

Tao Wang

http://www.w3.org/2001/XMLSchema#string

Xiao-Fang Yu

http://www.w3.org/2001/XMLSchema#string

Zuoxiang Xiao

http://www.w3.org/2001/XMLSchema#string

P2860

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons

Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities

APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication

A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins

Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication

APOBEC3G targets human T-cell leukemia virus type 1.

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

P304

7238-7248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02584-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6399328

http://www.w3.org/2001/XMLSchema#string

P698

17428847

http://www.w3.org/2001/XMLSchema#string

P932

1933265

http://www.w3.org/2001/XMLSchema#string